Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney function may affect how HRS-1893 works in heart disease

NCT ID NCT06775834

Knowledge-focused Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study looked at how HRS-1893 tablets are processed in people with mild or moderate kidney impairment compared to healthy subjects. The goal was to understand dosing needs for patients with hypertrophic cardiomyopathy who also have kidney issues. Twenty-four adults took part, and researchers measured drug levels in the blood and urine, along with safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HRS-1893 tablets
What this could lead to
If successful, this study could help doctors determine the right dose of HRS-1893 for people with kidney problems who have hypertrophic cardiomyopathy.
What could go wrong
This is a very early, small study (24 people) focused on drug levels and safety, not on treating the disease. It may not lead to any treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

24 people

The number who actually took part.

Started

Feb 2025

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Sign the informed consent before the trial, and fully understand the content, process and possible adverse reactions of the trial; 2. Male or female subjects aged 18 to 65 (including 18 and 65); 3. Body mass index (BMI) ranges from 19 kg/m2 to 28 kg/m2 (including 18 and 28); 4. The glomerular filtration rate should meet the following criteria (GFR, mL/min): Subjects with mild renal impairment: 60-89 mL/min; Subjects with moderate renal impairment: 30-59 mL/min. Exclusion Criteria: 1. Suspected allergy to the study drug or any component of the study drug; 2. Patients with cardiogenic shock, severe conduction block, sick sinus syndrome, heart failure, sustained tachyarrhythmia, torsades de pointes (Tdp) or ventricular tachycardia, history of clinically significant T wave changes, myocardial infarction, angina pectoris; 3. People with conditions associated with reduced neuromuscular transmission (myasthenia gravis, Lambert-Eaton syndrome, Duchenne muscular dystrophy); 4. Patients with a history of gastric or intestinal surgery that may affect drug absorption; 5. Participants with renal insufficiency who were judged by the investigator to be ineligible for the study; 6. Patients with large fluctuations or rapid deterioration of renal function within 2 weeks before administration, as judged by the investigator; 7. Subjects receiving renal replacement therapy within 3 months of the screening period or during the expected trial period; 8. Within 3 months before screening, patients with underlying diseases that induced chronic kidney disease and were poorly controlled according to the investigator's evaluation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic cardiomyopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertrophic cardiomyopathy

Contacts and locations

Locations

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.